Cover Image
市場調查報告書

Thrombotargets Europe SL:產品平台分析

Thrombotargets Europe SL - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 336715
出版日期 內容資訊 英文 24 Pages
訂單完成後即時交付
價格
Back to Top
Thrombotargets Europe SL:產品平台分析 Thrombotargets Europe SL - Product Pipeline Review - 2015
出版日期: 2015年06月30日 內容資訊: 英文 24 Pages
簡介

本報告提供Thrombotargets Europe SL 的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型治療藥的評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

Thrombotargets Europe SL的基本資料

Thrombotargets Europe SL概要

  • 主要資訊
  • 企業資料

Thrombotargets Europe SL:R&D概要

  • 主要的治療範圍

Thrombotargets Europe SL:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品

Thrombotargets Europe SL:開發中產品概況

  • 臨床實驗階段的開發中產品
    • 第二階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發中的產品/聯合治療模式

Thrombotargets Europe SL:藥物簡介

  • TT-173
  • TT-105
  • TT-111
  • TT-112
  • TT-120

Thrombotargets Europe SL:開發平台分析

  • 各給藥途徑
  • 各分子類型

Thrombotargets Europe SL:最近的開發平台趨勢

Thrombotargets Europe SL:暫停中的計劃

Thrombotargets Europe SL:總公司和子公司的所在地

附錄

目錄
Product Code: GMDHC07227CDB

Summary

Global Markets Direct's, 'Thrombotargets Europe SL - Product Pipeline Review - 2015', provides an overview of the Thrombotargets Europe SL 's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Thrombotargets Europe SL 's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Thrombotargets Europe SL including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Thrombotargets Europe SL 's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Thrombotargets Europe SL 's pipeline products

Reasons to buy

  • Evaluate Thrombotargets Europe SL 's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Thrombotargets Europe SL in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Thrombotargets Europe SL 's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Thrombotargets Europe SL and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Thrombotargets Europe SL
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Thrombotargets Europe SL and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Thrombotargets Europe SL Snapshot
    • Thrombotargets Europe SL Overview
    • Key Information
    • Key Facts
  • Thrombotargets Europe SL - Research and Development Overview
    • Key Therapeutic Areas
  • Thrombotargets Europe SL - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Thrombotargets Europe SL - Pipeline Products Glance
    • Thrombotargets Europe SL - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
    • Thrombotargets Europe SL - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Thrombotargets Europe SL - Drug Profiles
    • TT-173
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TT-105
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TT-111
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TT-112
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TT-120
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Thrombotargets Europe SL - Pipeline Analysis
    • Thrombotargets Europe SL - Pipeline Products by Route of Administration
    • Thrombotargets Europe SL - Pipeline Products by Molecule Type
  • Thrombotargets Europe SL - Recent Pipeline Updates
  • Thrombotargets Europe SL - Dormant Projects
  • Thrombotargets Europe SL - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Thrombotargets Europe SL, Key Information
  • Thrombotargets Europe SL, Key Facts
  • Thrombotargets Europe SL - Pipeline by Indication, 2015
  • Thrombotargets Europe SL - Pipeline by Stage of Development, 2015
  • Thrombotargets Europe SL - Monotherapy Products in Pipeline, 2015
  • Thrombotargets Europe SL - Phase II, 2015
  • Thrombotargets Europe SL - Preclinical, 2015
  • Thrombotargets Europe SL - Discovery, 2015
  • Thrombotargets Europe SL - Pipeline by Route of Administration, 2015
  • Thrombotargets Europe SL - Pipeline by Molecule Type, 2015
  • Thrombotargets Europe SL - Recent Pipeline Updates, 2015
  • Thrombotargets Europe SL - Dormant Developmental Projects,2015
  • Thrombotargets Europe SL, Other Locations
  • Thrombotargets Europe SL, Subsidiaries

List of Figures

  • Thrombotargets Europe SL - Pipeline by Top 10 Indication, 2015
  • Thrombotargets Europe SL - Pipeline by Stage of Development, 2015
  • Thrombotargets Europe SL - Monotherapy Products in Pipeline, 2015
  • Thrombotargets Europe SL - Pipeline by Top 10 Molecule Type, 2015
Back to Top